Monopar Therapeutics Inc ( (MNPR) ) just unveiled an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Monopar Therapeutics has secured an exclusive global license from Alexion Pharmaceuticals to develop and commercialize ALXN-1840, a promising treatment for Wilson disease, following a successful Phase 3 trial. The agreement entails an upfront payment of $4 million, equity in Monopar, and milestone payments up to $94 million, plus royalties. Despite regulatory challenges and the need for further funding, Monopar is focused on advancing ALXN-1840, targeting severe Wilson disease cases, potentially tapping into a niche market with high unmet medical needs.
For detailed information about MNPR stock, go to TipRanks’ Stock Analysis page.
